| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NB1 |
| Uniprot No | Q8N6Q3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-321aa |
| 氨基酸序列 | LLCQFGTVQHVWKVSDLPRQWTPKNTSCDSGLGCQDTLMLIESGPQVSLVLSKGCTEAKDQEPRVTEHRMGPGLSLISYTFVCRQEDFCNNLVNSLPLWAPQPPADPGSLRCPVCLSMEGCLEGTTEEICPKGTTHCYDGLLRLRGGGIFSNLRVQGCMPQPGCNLLNGTQEIGPVGMTENCNRKDFLTCHRGTTIMTHGNLAQEPTDWTTSNTEMCEVGQVCQETLLLLDVGLTSTLVGTKGCSTVGAQNSQKTTIHSAPPGVLVASYTHFCSSDLCNSASSSSVLLNSLPPQAAPVPG |
| 预测分子量 | 63.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与NB1重组蛋白相关的文献概览：
---
1. **文献名称**：*"CD177 (NB1) is a neutrophil cell surface antigen involved in HNA-2a alloimmunization"*
**作者**：Stroncek D.F., et al.
**摘要**：该研究通过重组表达CD177/NB1蛋白，揭示了其在嗜中性粒细胞表面的抗原性，并证明其与HNA-2a抗体介导的自身免疫性疾病的关联，为临床诊断提供依据。
2. **文献名称**：*"Recombinant NB1 protein expression and epitope mapping for autoimmune neutropenia analysis"*
**作者**：Caruccio L., et al.
**摘要**：通过大肠杆菌系统重组表达NB1蛋白，鉴定其关键抗原表位，发现其与新生儿同种免疫性中性粒细胞减少症中母体抗体的相互作用机制。
3. **文献名称**：*"Structural and functional characterization of recombinant NB1 glycoprotein"*
**作者**：Kahr W.H.A., et al.
**摘要**：利用哺乳动物细胞系统表达功能性NB1重组蛋白，分析其糖基化修饰对细胞黏附和信号传导的影响，阐明其在炎症反应中的分子机制。
---
**备注**：NB1(CD177)重组蛋白研究多聚焦于其作为嗜中性粒细胞特异性抗原的免疫学功能及疾病相关性。实际文献需通过PubMed或Web of Science以关键词“CD177 recombinant”或“NB1 glycoprotein”进一步检索。
NB1 recombinant protein, also known as neublastin-1 or artemin (ARTN), is a neurotrophic factor belonging to the glial cell line-derived neurotrophic factor (GDNF) family. This family includes GDNF, neurturin, and persephin, all of which signal through the RET receptor tyrosine kinase in complex with glycosylphosphatidylinositol (GPI)-anchored co-receptors (GFRα1-4). Artemin was first identified in 1998 for its role in promoting neuronal survival, differentiation, and axonal guidance, particularly in the peripheral and central nervous systems.
Structurally, NB1 is synthesized as a preproprotein that undergoes proteolytic processing to release a mature, biologically active domain. The mature protein contains seven conserved cysteine residues critical for forming a homodimer stabilized by interchain disulfide bonds, a hallmark of GDNF family ligands. Its 3D structure enables specific binding to the GFRα3 co-receptor, activating downstream RET-mediated signaling pathways involved in cell survival, proliferation, and synaptic plasticity.
Research highlights artemin's therapeutic potential in neurodegenerative disorders (e.g., Parkinson's disease, neuropathic pain) and nerve injury repair. Preclinical studies demonstrate its ability to rescue dopaminergic neurons, enhance peripheral nerve regeneration, and modulate pain sensitivity in animal models. However, challenges in clinical translation include optimizing delivery methods, minimizing off-target effects, and ensuring stable protein bioavailability. Current efforts focus on engineered variants and gene therapy approaches to overcome these limitations, positioning NB1 as a promising yet complex candidate for neurological therapeutics.
×
